Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

BACKGROUND: Immune checkpoint inhibitors have transformed the treatment landscape for many cancers, including metastatic melanoma, but have also opened the door for a diverse variety of immune-related adverse effects. CASE PRESENTATION: We describe the first reported case of presumed neurosarcoidosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Irena, Malinzak, Michael, Salama, April K. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069826/
https://www.ncbi.nlm.nih.gov/pubmed/30064495
http://dx.doi.org/10.1186/s40425-018-0390-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069826/
https://www.ncbi.nlm.nih.gov/pubmed/30064495
http://dx.doi.org/10.1186/s40425-018-0390-2

Ejemplares similares